Calendar Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq 21:30:00 03/05/2024 BST 5-day change 1st Jan Change
7.3 USD +1.53% Intraday chart for Altimmune, Inc. +0.55% -35.11%

Chart calendar Altimmune, Inc.

42fe9717a415b9da84dd36ce3205cf.fZArr9vdhrzjJ2L-eVJzB5dwXF4G6nT8eixRTHFXJpY.OP9q_bqOxM2ZZDjLNAtDd_oWLQ5Eqz2rFm8hDwknfvgn3Ezj7uro95cVOw~9049f6dd3356158f4a6dfb543ac1ceda

Upcoming events on Altimmune, Inc.

08/05/2024 21:00 BTIG Obesity Health Forum
08/05/2024 Q1 2024 Earnings Release
09/05/2024 13:30 Q1 2024 Earnings Call
15/05/2024 15:00 GLP-1 Based Therapeutics Summit - Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver Disea
16/05/2024 18:30 GLP-1 Based Therapeutics Summit - Attaining Product Differentiation through Improved Patient Segment
07/08/2024 Q2 2024 Earnings Release (Projected)
04/11/2024 Q3 2024 Earnings Release (Projected)
26/03/2025 Q4 2024 Earnings Release (Projected)
19/05/2025 Q1 2025 Earnings Release (Projected)

Past events on Altimmune, Inc.

27/03/2024 12:30 Q4 2023 Earnings Call
27/03/2024 11:00 Q4 2023 Earnings Release
05/01/2024 NASH-TAG Conference - Abstract No: #51
01/12/2023 13:30 MOMENTUM Phase 2 Trial Results Call
07/11/2023 13:30 Q3 2023 Earnings Call
07/11/2023 12:00 Q3 2023 Earnings Release
25/10/2023 20:00 H.C. Wainwright NASH Investor Conference - Fireside Chat
24/10/2023 15:00 H.C. Wainwright NASH Investor Conference
03/10/2023 15:30 European Association for the Study of Diabetes Meeting
28/09/2023 13:30 Annual General Meeting
13/09/2023 18:35 Morgan Stanley Global Healthcare Conference - Fireside Chat
06/09/2023 20:45 Wells Fargo Healthcare Conference - Fireside Chat
10/08/2023 13:30 Q2 2023 Earnings Call
10/08/2023 12:00 Q2 2023 Earnings Release
23/06/2023 07:30 EASL International Liver Congress
20/06/2023 16:00 Maxim Group Virtual Healthcare Conference
15/06/2023 00:00 Goldman Sachs Global Healthcare Conference - Fireside Chat
09/06/2023 13:30 Jefferies Global Healthcare Conference - Fireside Chat
30/05/2023 Novel Therapies For Type 2 Diabetes & Obesity Summit
17/05/2023 Piper Sandler Spring Biopharma Symposium

Annual results

Fiscal PeriodDecember 2019 2020 2021 2022 2023 2024
Net sales
Million USD
Released
Forecast
Spread
5,80
5,98
-2.92%
8,19
7,71
6.13%
4,41
1,18
274.08%
-0,07
0,05
-241.67%
0,43
0,34
24.04%

35,7

EBITDA
Million USD
Released
Forecast
Spread
0,00
0,00
-
0,00
0,00
-
-96,4
-92,2
-4.51%
-87,9
-89,3
1.53%
0,00
-83,1
-

-95,7

EBIT
Million USD
Released
Forecast
Spread
-21,5
-21,3
-0.68%
-54,8
-70,4
22.11%
-85,5
-97,5
12.28%
-87,7
-91,4
3.99%
-83,5
-93,9
11.09%

-61,8

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
-20,6
-20,4
-0.68%
-54,5
-69,9
22.08%
-97,1
-99,3
2.24%
-84,9
-91,2
6.88%
-88,4
-81,2
-8.96%

-52,3

Net income
Million USD
Released
Forecast
Spread
-20,5
-20,4
-0.69%
-49,0
-64,3
23.74%
-97,1
-98,7
1.64%
-84,7
-90,9
6.82%
-88,4
-81,1
-9.1%

-59,0

EPS
USD
Released
Forecast
Spread
-1,60
-1,52
-5.26%
-1,91
-2,59
26.3%
-2,35
-2,41
2.62%
-1,81
-2,04
11.09%
-1,66
-1,47
-13.18%

-0,94

Announcement Date27/03/2025/02/2115/03/2228/02/2327/03/24-

Quarterly results

Fiscal PeriodDecember 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales
Million USD
Released
Forecast
Spread
3,28
0,09
3528.54%
0,03
0,88
-96.38%
0,01
0,87
-99.08%
0,00
1,04
-99.81%
-0,11
0,03
-423.53%
0,02
0,00
-
0,01
0,00
100%
0,36
0,00
41993.02%
0,04
0,00
1628.97%

0,00


0,00


41,7


0,00


0,00

EBITDA
Million USD
Released
Forecast
Spread
-23,9
-19,7
-21.15%
-19,4
-17,9
-8.27%
-20,3
-20,9
2.67%
-24,9
-23,9
-4.15%
-23,3
-24,8
6.18%
-21,4
-23,9
10.45%
-17,5
-21,7
19.35%
-22,0
-18,1
-21.48%

-19,4


-21,8


-22,3


-22,8


-23,3




EBIT
Million USD
Released
Forecast
Spread
-20,7
-28,0
26.02%
-19,5
-24,1
19.1%
-20,4
-22,5
9.36%
-24,8
-23,8
-3.97%
-23,1
-26,3
12.07%
-21,8
-24,8
12.15%
-18,0
-24,3
25.94%
-22,5
-22,6
0.37%
-21,2
-34,9
39.23%

-23,7


-24,8


15,0


-28,6


-22,2

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
-23,9
-27,9
14.25%
-19,4
-24,1
19.38%
-20,1
-21,5
6.48%
-23,7
-23,8
0.4%
-21,7
-27,1
20.2%
-20,1
-24,6
18.35%
-16,1
-23,5
31.54%
-20,7
-21,6
4.4%
-31,6
-24,4
-29.94%

-22,9


-24,2


23,6


-29,0


-22,2

Net income
Million USD
Released
Forecast
Spread
-23,9
-27,0
11.38%
-19,4
-24,1
19.38%
-20,1
-21,8
7.82%
-23,5
-23,4
-0.51%
-21,7
-27,1
19.97%
-20,1
-24,5
18.02%
-16,1
-16,3
1.52%
-20,7
-21,5
3.79%
-31,6
-24,3
-30.25%

-22,8


-23,9


15,8


-28,2


-22,2

EPS
USD
Released
Forecast
Spread
-0,57
-0,65
12.08%
-0,44
-0,59
24.79%
-0,42
-0,50
15.15%
-0,48
-0,49
2.83%
-0,44
-0,54
18.22%
-0,40
-0,48
16.67%
-0,32
-0,45
29.41%
-0,39
-0,42
6.4%
-0,54
-0,38
-44%

-0,36


-0,36


0,19


-0,41


-0,36

Announcement Date15/03/2212/05/2211/08/2210/11/2228/02/2311/05/2310/08/2307/11/2327/03/24-----

Net sales - Quarter - Rate of surprise

Quarterly earnings - Rate of surprise

Net sales - Annual - Rate of surprise

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALT Stock
  4. Calendar Altimmune, Inc.